Skip to main content
Erschienen in: Cancer Causes & Control 5/2021

01.03.2021 | Original Paper

The incidence of skin melanoma in Gran Canaria (Canary Islands, Spain) is lower than expected in Southern Europe despite high-risk environmental conditions: an island-wide cross-sectional study

verfasst von: Mercè Grau-Pérez, Gregorio Carretero, Pablo Almeida, Elena Castro-González, María del Pilar de-la-Rosa-del-Rey, Jesús María González-Martín, Leopoldo Borrego

Erschienen in: Cancer Causes & Control | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The Canary Islands are a leading European touristic destination. The ultraviolet index (UVI) in the region is the highest in Spain, and similar to indexes registered in Australia and New Zealand, which hold the highest incidence of skin melanoma worldwide. Yet according to cancer registry data, the incidence in the Canary Islands in the late 1990s was the lowest in Spain (among the lowest in Europe) and about six times lower than in New Zealand.

Purpose

To analyze the incidence rates of skin melanoma in Gran Canaria island between 2007 and 2018.

Methods

The study was based in the two centres of the Canary Islands’ Healthcare Service centralizing melanoma care in Gran Canaria. We analyzed crude and age-standardized (ASR) incidence rates of invasive cutaneous melanoma for the period 2007–2018 following the inclusion criteria of the International Agency for Research on Cancer (IARC). Clinical and histological characteristics of melanoma patients were assessed.

Results

A total of 1058 patients were included. The incidence rates obtained matched the latest available Canary Islands’ cancer registry data, confirming its reliability (ASR, Segi-Doll world standard population: 6.4 cases per 100,000 habitants for 2008–2012). The incidence was also below the latest IARC predictions for Southern Europe (GLOBOCAN 2018). Histological characteristics of patients were similar to other Southern European series.

Conclusions

The incidence of skin melanoma in Gran Canaria is unexpectedly low for a Southern European population exposed to such a high UVI. Further research in the Canary Islands could provide insight into a better understanding of melanoma pathogenesis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Demunter C, Dimitrakopoulou (2019) Tourism. In: Kotzeva M, Brandmüller T, Önnerfors A (eds) Eurostat regional yearbook 2019. Publications Office of the European Union, Luxembourg, pp 144–149. https://doi.org/10.2785/411990 Demunter C, Dimitrakopoulou (2019) Tourism. In: Kotzeva M, Brandmüller T, Önnerfors A (eds) Eurostat regional yearbook 2019. Publications Office of the European Union, Luxembourg, pp 144–149. https://​doi.​org/​10.​2785/​411990
13.
Zurück zum Zitat Forman D, Bray F, Brewster DH et al (2014) Cancer incidence in five continents, vol X. International Agency for Research on Cancer, Lyon, France Forman D, Bray F, Brewster DH et al (2014) Cancer incidence in five continents, vol X. International Agency for Research on Cancer, Lyon, France
17.
Zurück zum Zitat Eurostat (2013) Revision of the European Standard Population. Report of Eurostat’s task force. Eurostat, Luxembourg Eurostat (2013) Revision of the European Standard Population. Report of Eurostat’s task force. Eurostat, Luxembourg
19.
Zurück zum Zitat Bray F, Colombet M, Mery L et al (2017) Cancer incidence in five continents, vol XI (electronic version). International Agency for Research on Cancer, Lyon Bray F, Colombet M, Mery L et al (2017) Cancer incidence in five continents, vol XI (electronic version). International Agency for Research on Cancer, Lyon
22.
Zurück zum Zitat World Health Organization (2002) Global Solar UV Index. A practical guide. World Health Organization, Geneva World Health Organization (2002) Global Solar UV Index. A practical guide. World Health Organization, Geneva
25.
Zurück zum Zitat McKenzie R (2017) UV radiation in the melanoma capital of the world: what makes New Zealand so different? In: AIP conference proceedings. American Institute of Physics, p 020003 McKenzie R (2017) UV radiation in the melanoma capital of the world: what makes New Zealand so different? In: AIP conference proceedings. American Institute of Physics, p 020003
26.
Zurück zum Zitat Lancet T (2018) GLOBOCAN 2018: counting the toll of cancer. Lancet 392:985CrossRef Lancet T (2018) GLOBOCAN 2018: counting the toll of cancer. Lancet 392:985CrossRef
28.
Zurück zum Zitat Population-Based Cancer Registry of the Canary Islands; Epidemiology and Prevention Department; Directorate-General for Public Health (2019) Estimates of Cancer Incidence in the Canary Islands, 2018 Population-Based Cancer Registry of the Canary Islands; Epidemiology and Prevention Department; Directorate-General for Public Health (2019) Estimates of Cancer Incidence in the Canary Islands, 2018
42.
Zurück zum Zitat Petersen B, Triguero-Mas M, Maier B et al (2015) Sun behaviour and personal UVR exposure among Europeans on short term holidays. J Photochem Photobiol B Biol 151:264–269 CrossRefPubMed Petersen B, Triguero-Mas M, Maier B et al (2015) Sun behaviour and personal UVR exposure among Europeans on short term holidays. J Photochem Photobiol B Biol 151:264–269 CrossRefPubMed
44.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJCK (eds) (2020) Melanoma of the skin (invasive). National Cancer Institute, Bethesda Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJCK (eds) (2020) Melanoma of the skin (invasive). National Cancer Institute, Bethesda
46.
Zurück zum Zitat Kaatsch P, Spix C, Katalinic A et al (2018) Cancer in Germany in 2013/2014, 11th edn. Robert Koch Institute, Berlin Kaatsch P, Spix C, Katalinic A et al (2018) Cancer in Germany in 2013/2014, 11th edn. Robert Koch Institute, Berlin
47.
Zurück zum Zitat Bray F, Kohler B, Ferlay J (2014) Data comparability and quality. In: Forman D, Bray F, Brewster DH et al (eds) Cancer incidence in five continents, vol X. International Agency for Research on Cancer, Lyon, pp 89–92 Bray F, Kohler B, Ferlay J (2014) Data comparability and quality. In: Forman D, Bray F, Brewster DH et al (eds) Cancer incidence in five continents, vol X. International Agency for Research on Cancer, Lyon, pp 89–92
48.
Zurück zum Zitat Iglesias-Pena N, Paradela S, Tejera-Vaquerizo A et al (2019) Cutaneous melanoma in the elderly: review of a growing problem. Actas Dermosifiliogr 110:434–447CrossRefPubMed Iglesias-Pena N, Paradela S, Tejera-Vaquerizo A et al (2019) Cutaneous melanoma in the elderly: review of a growing problem. Actas Dermosifiliogr 110:434–447CrossRefPubMed
49.
Zurück zum Zitat Lasithiotakis KG, Petrakis IE, Garbe C (2010) Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res 20:163–170CrossRefPubMed Lasithiotakis KG, Petrakis IE, Garbe C (2010) Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res 20:163–170CrossRefPubMed
Metadaten
Titel
The incidence of skin melanoma in Gran Canaria (Canary Islands, Spain) is lower than expected in Southern Europe despite high-risk environmental conditions: an island-wide cross-sectional study
verfasst von
Mercè Grau-Pérez
Gregorio Carretero
Pablo Almeida
Elena Castro-González
María del Pilar de-la-Rosa-del-Rey
Jesús María González-Martín
Leopoldo Borrego
Publikationsdatum
01.03.2021
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 5/2021
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-021-01403-7

Weitere Artikel der Ausgabe 5/2021

Cancer Causes & Control 5/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.